Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

5.30
-0.1800-3.28%
Pre-market: 5.25-0.0500-0.94%07:07 EDT
Volume:829.74K
Turnover:4.45M
Market Cap:119.48M
PE:-0.30
High:5.57
Open:5.40
Low:5.25
Close:5.48
52wk High:10.99
52wk Low:3.51
Shares:22.54M
Float Shares:21.40M
Volume Ratio:0.16
T/O Rate:3.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9300
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-41.56%
PB:-0.41
PE(LYR):-0.30

Loading ...

Karyopharm Therapeutics Grants Stock Options and RSUs to New Employees

Reuters
·
Dec 02, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 02, 2025

Karyopharm Therapeutics Joins Piper Sandler Annual Healthcare Conference

Reuters
·
Dec 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 20, 2025

Karyopharm Therapeutics Q3 Net Income USD -33.127 Million

Reuters
·
Nov 20, 2025

Karyopharm Therapeutics Highlights Selinexor Pipeline Progress and Myelofibrosis Opportunity in New Corporate Presentation

Reuters
·
Nov 15, 2025

Karyopharm Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Nov 05, 2025

Karyopharm Therapeutics Inc : Jefferies Adjusts Target Price to $15 From $4.5 to Reflect Reverse Stock Split

THOMSON REUTERS
·
Nov 04, 2025

RBC Cuts Price Target on Karyopharm Therapeutics to $19 From $30, Keeps Outperform Rating

MT Newswires Live
·
Nov 04, 2025

Karyopharm Therapeutics Inc : RBC Cuts Target Price to $19 From $30

THOMSON REUTERS
·
Nov 04, 2025

BRIEF-Karyopharm Therapeutics Files Prospectus For Resale

Reuters
·
Nov 04, 2025

Karyopharm Therapeutics Files Prospectus for Resale From Time to Time of up to 9.57 Mln Common Stock by Selling Stockholders-SEC Filing

THOMSON REUTERS
·
Nov 04, 2025

Karyopharm Therapeutics Grants 800 RSUs to New Employee Under Inducement Plan

Reuters
·
Nov 04, 2025

Karyopharm sees FY25 revenue $140M-$155M, consensus $150.22M

TIPRANKS
·
Nov 03, 2025

Karyopharm Therapeutics Reports Third Quarter Net Loss of $33.1 Million on Revenue of $44 Million

Reuters
·
Nov 03, 2025

BRIEF-Karyopharm Therapeutics Q3 Net Income USD -33.127 Million

Reuters
·
Nov 03, 2025

Karyopharm Therapeutics Inc - Reaffirms 2025 Revenue Guidance

THOMSON REUTERS
·
Nov 03, 2025

Karyopharm Therapeutics Q3 Product Revenue USD 32.032 Million

THOMSON REUTERS
·
Nov 03, 2025

Karyopharm Therapeutics Inc expected to post a loss of $3.13 a share - Earnings Preview

Reuters
·
Oct 31, 2025

Karyopharm Therapeutics Completes Financing Transactions for Growth

TIPRANKS
·
Oct 15, 2025